Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
Faculty (Bladder Cancer) Terence Friedlander, MD
Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Division of Hematology/Oncology
Zuckerberg San Francisco General Hospital
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California
Matthew D Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Co-Leader, Bladder Cancer Center of Excellence
Associate Director, Translational Research
The Tisch Cancer Institute
New York, New York
Faculty (Prostate Cancer) Neeraj Agarwal, MD, FASCO
Professor of Medicine
Senior Director for Clinical Research
Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute University of Utah (NCI-CCC)
Salt Lake City, Utah
Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina
Moderator Elisabeth I Heath, MD
Chair, Department of Oncology
Mayo Clinic
Rochester, Minnesota
This activity is supported by an educational grant from Astellas and Pfizer Inc.
MODULE 1: Role of Antibody-Drug Conjugates (ADCs) in Front-Line Therapy for Metastatic Urothelial Bladder Cancer (mUBC)
Long-term outcomes with historical up-front treatment approaches for patients with mUBC
Biological rationale for the evaluation of ADCs in combination with immune checkpoint inhibitors for previously untreated mUBC
Key results from cohort K of the EV-103/KEYNOTE-869 study of enfortumab vedotin (EV) alone and in combination with pembrolizumab for treatment-naïve, cisplatin-ineligible patients with mUBC
Published efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 study comparing EV/pembrolizumab to chemotherapy for patients with previously untreated mUBC who were eligible for cisplatin- or carboplatin-containing chemotherapy
Recent FDA approval of EV/pembrolizumab as front-line therapy for mUBC regardless of cisplatin eligibility; optimal integration into practice
Incidence of treatment-related adverse events of special interest, such as skin reactions, peripheral neuropathy, ocular disorders and hyperglycemia, observed with combined EV and pembrolizumab in the up-front setting; appropriate monitoring and management strategies
MODULE 2: Evidence-Based Use of ADCs for Relapsed/Refractory (R/R) mUBC
Key factors in selecting and sequencing available therapies for patients with progressive mUBC
Long-term outcomes from the Phase III EV-301 study evaluating EV versus chemotherapy for patients with previously treated advanced UBC
Optimal integration of EV into current management algorithms for R/R mUBC
Frequency of HER2 expression in mUBC; optimal timing of and approach to testing
Outcomes observed with trastuzumab deruxtecan (T-DXd) in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial
Recent FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for mUBC management
Mechanism of action and structural components of the HER2-targeted ADC disitamab vedotin
Available efficacy and safety data with disitamab vedotin alone and in combination with anti-PD-1/PD-L1 antibodies for HER2-positive mUBC
FDA breakthrough therapy designation for disitamab vedotin for platinum-pretreated HER2-positive locally advanced or metastatic UBC; potential clinical role
MODULE 3: Evolving Role of Treatment Intensification with Androgen Receptor (AR) Pathway Inhibitors for Nonmetastatic and Metastatic Prostate Cancer
Rationale for the evaluation of treatment intensification with AR pathway inhibitors combined with androgen deprivation therapy (ADT) for patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC)
Major efficacy and safety findings from the Phase III EMBARK trial evaluating enzalutamide and leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy
FDA approval and optimal application in clinical practice of enzalutamide with and without ADT
Clinical, biological and practical factors guiding the selection of therapy for metastatic hormone-sensitive prostate cancer (mHSPC)
Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC; appropriate integration of these therapies into practice
Published outcomes from the Phase III ARANOTE study evaluating the addition of darolutamide to ADT for patients with mHSPC; clinical implications
Key efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy
MODULE 4: Optimal Integration of PARP Inhibitors into Therapy for Prostate Cancer
Biological rationale for combining PARP inhibitors with AR pathway inhibitors in therapy for prostate cancer
Similarities and differences in the designs and eligibility criteria of the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials combining olaparib and abiraterone, niraparib and abiraterone and talazoparib and enzalutamide, respectively, in the first-line setting for metastatic castration-resistant prostate cancer (mCRPC)
Key efficacy and safety findings from PROpel, MAGNITUDE and TALAPRO-2 in patients with and without BRCA and other homologous recombination repair gene mutations; emerging overall survival data from TALAPRO-2
FDA approvals of olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for patients with mCRPC; individualized selection among these approaches
Published results from the Phase II BRCAAway trial comparing abiraterone, olaparib and the combination for patients with mCRPC with DNA repair defects; implications for clinical practice
Ongoing Phase III studies, including AMPLITUDE and TALAPRO-3, evaluating PARP inhibitors in combination with secondary hormonal therapy in earlier settings
Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of bladder and prostate cancers.
Learning Objectives
Upon completion of this activity, participants should be able to
Recognize the incidence of nectin-4 expression in urothelial bladder cancer (UBC), and appreciate the scientific justification for the development of antibody-drug conjugates (ADCs) targeting this novel biomarker.
Interrogate published efficacy and safety findings with anti-PD-1/PD-L1 antibodies in combination with ADC therapy as first-line treatment for metastatic UBC, and consider the current role of this strategy.
Review available research findings with HER2-directed ADCs for patients with advanced UBC, and optimally integrate these novel agents into management algorithms.
Appraise published research on the optimal management of biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients about the potential benefits of FDA-approved systemic treatment options.
Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic castration-resistant prostate cancer harboring a homologous recombination repair gene alteration, and discern the current role of this treatment approach.
Recall the design of ongoing clinical trials evaluating novel ADCs for advanced UBC or hormonal therapy-based approaches for prostate cancer, and counsel appropriate patients about availability and participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY
— Dr Agarwal has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Armstrong — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Cytogen Corporation, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Curium, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc.
Dr Friedlander — Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Pfizer Inc; Contracted Research: Bicycle Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics.
Dr Galsky — Advisory Committees: AbbVie Inc, Aktis Oncology, Alligator Bioscience, Analog Devices Inc, Asieris Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bicycle Therapeutics, Bristol Myers Squibb, Curis Inc, Daiichi Sankyo Inc, Dragonfly Therapeutics, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Merck, Numab Therapeutics AG, Pfizer Inc, Rappta Therapeutics, Seagen Inc, Silverback Therapeutics, UroGen Pharma, Veracyte Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Merck, Novartis.
MODERATOR
— Dr Heath — Advisory/Consulting: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Sanofi; Honoraria/Paid Travel: Astellas, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Sanofi, Seagen Inc; Institutional Research Support: Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffman-La Roche Ltd, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Steering Committees: Janssen Biotech Inc; Speakers Bureaus: Sanofi; Nonrelevant Financial Relationships: Calibr-Skaggs Institute for Innovative Medicines.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by an educational grant from Astellas and Pfizer Inc.
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600
Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2025 ASCO Genitourinary Cancers Symposium is taking place.
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of bladder and prostate cancers.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ASCO Genitourinary Cancers Symposium.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2025 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
